SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. 2008

Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease whose prevalence has increased markedly. We reported previously that fatty acid synthesis was enhanced in NAFLD with the accumulation of fatty acids. To clarify the disorder, we evaluated the expression of genes regulating fatty acid synthesis by real-time PCR using samples from NAFLD (n=22) and normal liver (control; n=10). A major regulator of fatty acids synthesis is sterol regulatory element-binding protein-1c (SREBP-1c). Its expression was significantly higher in NAFLD, nearly 5-fold greater than the controls. SREBP-1c is positively regulated by insulin signaling pathways, including insulin receptor substrate (IRS)-1 and -2. In NAFLD, IRS-1 expression was enhanced and correlated positively with SREBP-1c expression. In contrast, IRS-2 expression decreased by 50% and was not correlated with SREBP-1c. Forkhead box protein A2 (Foxa2) is a positive regulator of fatty acid oxidation and is itself negatively regulated by IRSs. Foxa2 expression increased in NAFLD and showed a negative correlation with IRS-2, but not with IRS-1, expression. It is known that SREBP-1c is negatively regulated by AMP-activated protein kinase (AMPK) but expression levels of AMPK in NAFLD were almost equal to those of the controls. These data indicate that, in NAFLD, insulin signaling via IRS-1 causes the up-regulation of SREBP1-c, leading to the increased synthesis of fatty acids by the hepatocytes; negative feedback regulation via AMPK does not occur and the activation of Foxa2, following a decrease of IRS-2, up-regulates fatty acid oxidation.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009097 Multienzyme Complexes Systems of enzymes which function sequentially by catalyzing consecutive reactions linked by common metabolic intermediates. They may involve simply a transfer of water molecules or hydrogen atoms and may be associated with large supramolecular structures such as MITOCHONDRIA or RIBOSOMES. Complexes, Multienzyme
D010750 Phosphoproteins Phosphoprotein
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D005234 Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. Liver Steatosis,Steatohepatitis,Steatosis of Liver,Visceral Steatosis,Liver Steatoses,Liver, Fatty,Steatohepatitides,Steatoses, Liver,Steatoses, Visceral,Steatosis, Liver,Steatosis, Visceral,Visceral Steatoses
D005246 Feedback A mechanism of communication within a system in that the input signal generates an output response which returns to influence the continued activity or productivity of that system. Feedbacks
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
January 2021, Frontiers in molecular biosciences,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
October 2023, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
December 2023, ACS omega,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
August 2019, Biochemical and biophysical research communications,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
October 2009, Free radical biology & medicine,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
October 2016, American journal of physiology. Endocrinology and metabolism,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
November 2023, Biochemical and biophysical research communications,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
September 2019, Free radical biology & medicine,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
May 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Motoyuki Kohjima, and Nobito Higuchi, and Masaki Kato, and Kazuhiro Kotoh, and Tsuyoshi Yoshimoto, and Tatsuya Fujino, and Masayoshi Yada, and Ryoko Yada, and Naohiko Harada, and Munechika Enjoji, and Ryoichi Takayanagi, and Makoto Nakamuta
June 2022, International journal of molecular sciences,
Copied contents to your clipboard!